jRCT2031220471
Untitled Trial
Assessment of Safety, Tolerability, and Efficacy Measured by Amyloid Reduction of LY3372993 in Early Symptomatic Alzheimer's Disease (J1G MC LAKC)
Eli Lilly Japan K.K.·Japan Registry Clinical TrialRecruiting
Study focus
- Disease/Condition
- Alzheimer's Disease
- Study type
- Interventional
Sponsor & location
- Primary sponsor
- Eli Lilly Japan K.K.
- Location
- United States of America
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
ICD-10 classifications
Alzheimer diseaseAlzheimer disease, unspecifiedOther Alzheimer diseaseDementia in Alzheimer diseaseDementia in Alzheimer disease, unspecified
Data source
- Registry
- Japan Registry Clinical Trial
- Trial ID
- jRCT2031220471
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for jRCT2031220471 through Pure Global AI's free database. This phase not specified trial is sponsored by Eli Lilly Japan K.K. and is currently Recruiting. The study focuses on Alzheimer's Disease.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Japan Registry Clinical Trial data, helping medical device and pharmaceutical companies navigate clinical research efficiently.